Key result
Direct oral anticoagulants are emerging as a new therapeutic option for the prevention and treatment of cancer-associated venous thromboembolism compared to standard low-molecular-weight heparin.
Why the study?
Anticoagulation in cancer patients is challenging due to risks of VTE recurrence and bleeding, and DOACs have recently emerged as new options alongside standard LMWH.
What are the recent advances in the prevention and treatment of cancer-associated venous thromboembolism using DOACs and LMWH?
What are the recent advances in the prevention and treatment of cancer-associated venous thromboembolism using DOACs and LMWH?
Answers are grounded in this paper and cite their sources.
This review highlights the emerging role of DOACs as an alternative to LMWH for the prevention and treatment of cancer-associated thrombosis.
Venous thromboembolism (VTE) is a common cause of morbidity and mortality in cancer patients and leads to a significant increase in health care costs. Cancer patients often suffer from multiple co-morbidities and have both a greater risk of VTE recurrence and bleeding compared to non-cancer patients. Anticoagulation is therefore challenging. For many years, long-term therapy with Low-Molecular-Weight Heparin (LMWH) was the standard of care for the management of cancer-associated VTE. Direct oral anticoagulants (DOAC), which offer the convenience of an oral administration and have a rapid onset of action, have recently been proposed as a new option in this setting. Head-to-head comparisons between DOAC and LMWHs for the treatment of established VTE are now available, and data on the efficacy and safety of these drugs for primary prophylaxis of VTE in ambulatory cancer patients receiving systemic anticancer therapy are emerging. This narrative review aims to summarize the main recent advances in the prevention and treatment of cancer-associated VTE, including recent data on the use of individualized factors to stratify the risk of VTE in each individual patient, quality-of-life in patients treated with LMWH, and the place that DOACs will likely take in the cancer-associated VTE management landscape.
No takes yet. Share an insight, caveat, or question.
Frère et al. (2019) conducted a review in Cancer-associated venous thromboembolism. Direct oral anticoagulants (DOAC) vs. Low-Molecular-Weight Heparin (LMWH) was evaluated. Direct oral anticoagulants are emerging as a new therapeutic option for the prevention and treatment of cancer-associated venous thromboembolism compared to standard low-molecular-weight heparin.
Synapse has enriched 10 related papers. Consider them for comparative context: